Tag: Clare O’Brien
Three firms act on BioNTech’s USD950m China partner buyout
A&O Shearman, Goodwin, and Conyers are advising BioNTech on its $950M buyout of a Chinese cancer drug partner to rival Merck
A&O Shearman, Goodwin, and Conyers are advising BioNTech on its $950M buyout of a Chinese cancer drug partner to rival Merck
South Korea’s maritime hub status grows with advanced ports, shipbuilding strength, trade volumes and dispute resolution.
Follow us on LinkedIn